Moreover, previous studies reported that the use of tumor necrosis factor (TNF) or interleukin (IL)-6 inhibitors was not associated with an increased risk of cancer development in patients with RA, even TNF inhibitor was associated with a lower cancer incidence (Choi et al., 2022; Huss et al., 2022). This evidence concerns the gene TNF and rheumatoid arthritis.